Maharashtra Herald

Severe Asthma Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

 Breaking News
  • No posts were found

Severe Asthma Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

October 15
00:40 2022
Severe Asthma Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market
Severe Asthma Market
DelveInsight’s Severe Asthma – Market Insights, Epidemiology, and Market Forecast–2032 report deliver an in-depth understanding of the Severe Asthma, historical and forecasted epidemiology as well as the Severe Asthma market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

DelveInsight’s Severe Asthma – Market Insights, Epidemiology, and Market Forecast–2032 report deliver an in-depth understanding of the Severe Asthma, historical and forecasted epidemiology as well as the Severe Asthma market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

 

The Severe Asthma market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Severe Asthma market size from 2019 to 2032. The Report also covers current Severe Asthma treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Some of the key facts of the Severe Asthma  Syndrome Market Report

  • The diagnosed prevalent population was further divided into intermittent, mild, moderate, and severe cases based on their disease severity. It was observed that intermittent cases of asthma were the most prevalent cases in the US
  • Among the European countries, the UK accounted for the highest number of asthma diagnosed prevalent (adult + pediatric) cases (5,884,988), followed by France (4,117,330) in 2021. In contrast, Spain accounted for the lowest number of cases of the total diagnosed prevalent population in the EU-5 for 2021.
  • In 2021, Japan had 7,122,971 diagnosed prevalent cases of Severe Asthma.

Key Benefits of the Report:

  • The report covers a descriptive overview of Severe Asthma, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into Severe Asthma epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Severe Asthma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Severe Asthma market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Severe Asthma market.

Got queries? Click here to know more about the Severe Asthma Market Trends

Severe Asthma Overview

Asthma is the most common chronic respiratory disease all over the globe. It affects the airways in the lungs, which become inflamed and narrowed due to various triggers, making it harder for air to flow out. It is a complex activity between airway inflammation and airway remodeling that results in airway hyper-responsiveness (AHR), which further leads to variable and excessive airway contraction. The characteristic symptoms of asthma include wheezing, shortness of breath, cough, a sensation of tightness in the chest, straining of neck and chest muscles, rapid breathing, and changes in heart rate.

Based upon response to treatment, severe asthma is further classified into type-2 inflammation and non-type-2 inflammation. Type-2 inflammation includes allergic asthma and eosinophilic asthma (or e-asthma) while non-type-2 inflammation includes non-eosinophilic asthma.

Diagnosis of severe asthma is difficult as careful physiologic characterization of the patient is lacking. In most cases, diagnosis depends on the symptoms and the response to treatment already being administered. Peripheral airway resistance (Rp) measurements, computed tomography, noninvasive magnetic resonance, PET scans, sputum induction, and bronchoscopy help diagnose asthma and related airway inflammation. Various biomarker tests are recommended to determine the asthma phenotype.

Severe Asthma Epidemiological Insights

 

  • Severe Asthma is less prevalent than mild and moderate asthma, affecting approximately 10% of all individuals with asthma. Due to the multiplicity of definitions, there is a high underdiagnoses of severe asthma. According to GINA guidelines, severe asthma is defined as asthma that is uncontrolled despite adherence to optimized high dose ICS-LABA therapy and treatment of contributory factors, or that worsens when high dose therapy is decreased.
  • Total diagnosed prevalent (adult + pediatric) cases of asthma in the 7MM was observed to be 54,215,617 cases in 2021. These cases are expected to increase by 2032
  • Among 7MM, the United States had the highest diagnosed cases of adult asthma with 20,868,845 cases in 2021. The cases are expected to increase by 2032.
  • Assessments as per DelveInsight’s analysts show that in the US, there were approximately 1,237,778 cases of Type-2 inflammation and non-type-2 inflammation severe asthma each in 2021, which are expected to increase significantly by 2032.

Severe Asthma Epidemiological Segmentation 

  • Total Severe Asthma diagnosed prevelant cases
  • Total Severe Asthma severity specific diagnosed cases
  • Total Severe Asthma type specific diagnosed prevelant cases

Severe AsthmaMarket Outlook

The treatment aims to reduce the symptom burden (i.e., good symptom control while maintaining normal activity levels) and minimize the risk of adverse events such as exacerbations, fixed airflow limitation, and treatment side effects. Guideline-based management of asthma focuses on disease severity and choosing the appropriate medical therapy to control symptoms and reduce the risk of exacerbations. Severe asthmatics require higher doses of inhalers and often require medications (anticholinergics) that relax the muscles around the airways, making it easier to breathe. Long-term usage of combination inhaled controller medications may not be sufficient for treating severe asthmatics, and long-term use of oral steroids carries the risk of increased side effects.

Learn more by requesting for sample @ Severe Asthma Market Landscape

Severe Asthma Key Companies

  • GSK
  • AstraZeneca
  • 4D Pharma
  • Novartis
  • And many more

 

Severe Asthma Therapies 

 

  • GSK3511294 (depemokimab)
  • PT027
  • PT010
  • MRx-4DP0004
  • CSJ117 (Ecleralimab)
  • And many more

 

 Table of Contents

  • Key Insights 
  • Report Introduction 
  • Executive Summary of Severe Asthma  Syndrome 
  • Disease Background and Overview
  • Epidemiology and patient population
  • The United States 
  • EU 5
  • Severe Asthma  Syndrome  Emerging Therapies
  • Severe Asthma  Syndrome Market Outlook
  • Market Access and Reimbursement of Therapies
  •  Appendix
  •  Hemophilia Report Methodology
  •  DelveInsight Capabilities
  •  Disclaimer
  •  About DelveInsight

Click here to read more about Severe Asthma

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/